Summary Apolipoprotein E (apoE), a 34 kDa circulating glycoprotein of 299 amino acids,
predominantly synthesised in the liver, associates with triglyceride-rich lipoproteins to …

Abstract Apolipoprotein E (apoE), a 34 kDa glycoprotein, mediates hepatic and extrahepatic
uptake of plasma lipoproteins and cholesterol efflux from lipid-laden macrophages. In …

In humans, three paraoxonase (PON1, PON2, and PON3) genes are clustered on
chromosome 7 at a locus that spans a distance around 170 kb. These genes are highly …

Atherosclerosis is a leading cause of cardiovascular disease worldwide, and
hypercholesterolemia is a major risk factor. Preventive treatments mainly focus on the …

The ongoing debate on whether non-alcoholic fatty liver disease (NAFLD) is an active
contributor or an innocent bystander in the development of cardiovascular disease (CVD) …

Since the seminal breakthrough of treating diabetic patients with insulin in the 1920s, there
has been great interest in developing other proteins and their peptide mimetics as therapies …

Chronic inflammatory diseases, such as rheumatoid arthritis, steatohepatitis, periodontitis,
chronic kidney disease, and others are associated with an increased risk of atherosclerotic …

The prevalence and burden of CNS disorders are increasing significantly due to the
increase in life span and population. The contemporary need in CNS drug discovery is to …

Despite recent advancements in vascular disease treatments, thrombosis and poor long-
term vessel patency remain significant barriers to effective endovascular intervention …

Mimetic peptides are potential therapeutic agents for atherosclerosis. d-[113–122]
apolipoprotein (apo) J (d-[113–122] apoJ) is a 10-residue peptide that is predicted to form a …